Iteos Therapeutics Inc (NASDAQ:ITOS) — Market Cap & Net Worth
Market Cap & Net Worth: Iteos Therapeutics Inc (ITOS)
Iteos Therapeutics Inc (NASDAQ:ITOS) has a market capitalization of $448.68 Million ($448.68 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #12876 globally and #3168 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Iteos Therapeutics Inc's stock price $10.15 by its total outstanding shares 44205400 (44.21 Million). Also see Iteos Therapeutics Inc total assets for a full breakdown of the balance sheet.
Iteos Therapeutics Inc Market Cap History: 2020 to 2025
Iteos Therapeutics Inc's market capitalization history from 2020 to 2025. Data shows change from $1.50 Billion to $448.68 Million (-11.61% CAGR). Also see Iteos Therapeutics Inc (ITOS) cash conversion ratio for how efficiently the company converts equity into cash flow.
Index Memberships
Iteos Therapeutics Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.02% | #349 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #1269 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.02% | #190 of 263 |
Weight: Iteos Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Iteos Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Iteos Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Iteos Therapeutics Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
9.70x
Iteos Therapeutics Inc's market cap is 9.70 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $2.06 Billion | $344.77 Million | $214.52 Million | 5.97x | 9.59x |
| 2022 | $863.33 Million | $267.63 Million | $96.65 Million | 3.23x | 8.93x |
| 2023 | $484.05 Million | $12.60 Million | -$112.64 Million | 38.43x | N/A |
| 2024 | $339.50 Million | $35.00 Million | -$134.41 Million | 9.70x | N/A |
Competitor Companies of ITOS by Market Capitalization
Companies near Iteos Therapeutics Inc in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Iteos Therapeutics Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Iteos Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Iteos Therapeutics Inc Historical Marketcap From 2020 to 2025
Between 2020 and today, Iteos Therapeutics Inc's market cap moved from $1.50 Billion to $ 448.68 Million, with a yearly change of -11.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $448.68 Million | +32.16% |
| 2024 | $339.50 Million | -29.86% |
| 2023 | $484.05 Million | -43.93% |
| 2022 | $863.33 Million | -58.05% |
| 2021 | $2.06 Billion | +37.67% |
| 2020 | $1.50 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 28th, 2026 the market cap of Iteos Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $448.68 Million USD |
| MoneyControl | $448.68 Million USD |
| MarketWatch | $448.68 Million USD |
| marketcap.company | $448.68 Million USD |
| Reuters | $448.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Iteos Therapeutics Inc
iTeos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of T-cell immunoreceptor with Ig and ITIM domains (TIGIT), as well as engages the Fc gamma receptor to activate dendritic cells, natural killer cells, T lym… Read more